PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
Phase 1
Completed
- Conditions
- SchizophreniaSchizo-affective Disorder
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00463372
- Locations
- 🇿🇦
Pfizer Investigational Site, George, South Africa
A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers
Phase 1
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT00463918
- Locations
- 🇬🇧
Pfizer Investigational Site, Slough, Berkshire, United Kingdom
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 187
- Registration Number
- NCT00460603
- Locations
- 🇺🇸
Pfizer Investigational Site, Vancouver, Washington, United States
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Completed
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 356
- Registration Number
- NCT00460798
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
Phase 3
Completed
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00460486
- Locations
- 🇵🇱
Niepubliczny ZOZ "VITA", Olsztyn, Poland
🇵🇱Centrum Badan Farmakologii Klinicznej monipol, Krakow, Poland
🇵🇱Niepubliczny ZOZ "Atarax" s.c., Olsztyn, Poland
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 501
- Registration Number
- NCT00460408
- Locations
- 🇸🇪
Pfizer Investigational Site, Västerås, Sweden
Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Device: Enbrel 50 mg Prefilled SyringeDevice: Enbrel 50 mg Autoinjector
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT00459706
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Phase 3
Completed
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 960
- Registration Number
- NCT00457392
- Locations
- 🇬🇧
Pfizer Investigational Site, Yeovil, Somerset, United Kingdom
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 609
- Registration Number
- NCT00457457
- Locations
- 🇬🇧
Pfizer Investigational Site, Bristol, United Kingdom
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 768
- Registration Number
- NCT00457691
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath